Biological E starts human trials of COVID-19 vaccine in India
Category: #healthcare  By Akshay Kedari  Date: 2020-11-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biological E starts human trials of COVID-19 vaccine in India

Biological E. Limited, an India-based vaccines and pharmaceutical company, has reportedly started phase I and II clinical trials of COVID-19 sub-unit vaccine candidate after getting the Drugs Controller General of India’s nod.

The vaccine manufacturer has teamed up with U.S. based Dynavax Technologies Corporation (Dynavax) and Baylor College of Medicine for making the vaccine.

Aimed at boosting the immune response, the vaccine candidate incorporates BCM Ventures’ antigen in-licensed, integrated commercialization team of Baylor College of Medicine and Dynavax’s sophisticated adjuvant CpG 1018.

The clinical trial will apparently use three dose levels in around 360 healthy subjects aged 18-65 to assess the immunogenicity and safety of the vaccine candidate. For the uninitiated, the vaccination schedule includes two doses for each study participant which are administered through intramuscular injection 28 days apart.

Dr. Maria Elena Bottazzi, National School of Tropical Medicine’s associated dean at Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development’s co-director, threw light on the ascend into human trials and dubbed it as “an important milestone,” noting the successful transfer of technology with BE to develop an effective, safe and affordable vaccine.

Mahima Datla, managing director of Biological E. Limited, expressed her elation to have transitioned to clinical trials and provide a likely alternative for the prophylaxis COVID-19.

Ryan Spencer, chief executive officer of Dynavax, was quoted to be proudful to contribute CpG 1018 to underpin growth of an adjuvanted vaccine to negate COVID-19. He went on to claim that the capability of CpG 1018 to bolster the immune response to come up with lifelong immunity and more antibodies will reduce the dose of antigen required, thereby leveraging vaccination to a large number of people.

The results of the clinical trial will potentially be available by February 2021.

Source credit:

https://www.bcm.edu/news/biological-e-limited-and-baylor-covid-19-vaccine-begins-clinical-trial-in-india

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Five Prime announces pre-clinical data of anti-CCR8 FPA157 program
Five Prime announces pre-clinical data of anti-CCR8 FPA157 program
By Akshay Kedari

Five Prime Therapeutics, Inc. has recently revealed the 1st pre-clinical data of the anti-CCR8 FPA15...

Opear reveals 2 promotions to boost patients’ access to healthcare
Opear reveals 2 promotions to boost patients’ access to healthcare
By Akshay Kedari

Opear MD, a membership-based app, has reportedly announced two promotions to improve affordability a...

FDA extends Ryplazim BLA review period for Liminal Biosciences
FDA extends Ryplazim BLA review period for Liminal Biosciences
By Akshay Kedari

Clinical stage biopharmaceutical major, Liminal Biosciences Inc., has reportedly announced the exten...